Author:
Miki Kenta,Sasaki Hiroshi,Kido Masahito,Takahashi Hiroyuki,Aoki Manabu,Egawa Shin
Funder
Astellas Pharma Inc. (Tokyo, Japan)
AstraZeneca K.K. (Osaka, Japan)
Takeda Pharmaceutical Co., Ltd. (Osaka, Japan)
Nihon Medi-Physics Co., Ltd. (Tokyo, Japan)
Foundation for Biomedical Research and Innovation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference40 articles.
1. Mottet N, Bastian PJ, Bellmunt J, van den Bergh R.C.N, Bolla M, van Casteren NJ, P: European Association of Urology. Guidelines on prostate cancer. [ https://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf ]
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline). Prostate cancer Version 3. [ http://www.cus.cz/wp-content/uploads/2012/10/NCCN-C61-2014.pdf ]
3. Payne H, Mason M. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer. 2011;105:1628–34.
4. Saito S, Nagata H, Kosugi M, Toya K, Yorozu A. Brachytherapy with permanent seed implantation. Int J Clin Oncol. 2007;12:395–407.
5. Miki K, Kiba T, Sasaki H, Kido M, Aoki M, Takahashi H, Miyakoda K, Dokiya T, Yamanaka H, Fukushima M, Egawa S. Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer. 2010;10:572.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献